Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study

Sophie Norenstedt, Ylva Pernow, Kerstin Brismar, Maria Sääf, Ayla Ekip, Fredrik Granath, Jan Zedenius, Inga-Lena Nilsson, Sophie Norenstedt, Ylva Pernow, Kerstin Brismar, Maria Sääf, Ayla Ekip, Fredrik Granath, Jan Zedenius, Inga-Lena Nilsson

Abstract

Background: Vitamin D insufficiency may increase the risk for cardio metabolic disturbances in patients with primary hyperparathyroidism (PHPT).

Objective: To analyze the vitamin D status and indices of the metabolic syndrome in PHPT patients and the effect of vitamin D supplementation after parathyroid adenomectomy (PTX).

Design and methods: Double-blinded, randomized clinical trial (ClinicalTrials.gov identifier: NCT00982722) performed at Karolinska University Hospital, Sweden, April 2008 to November 2011. One hundred and fifty consecutive patients with PHPT (119 women) were randomized after PTX, 75 to oral treatment with calcium carbonate 1000 mg daily and 75 to calcium carbonate 1000 mg and cholecalciferol 1600 IU daily over 12 months. Changes in metabolic profile and ambulatory blood pressure (BP) were analyzed. Main outcome measures were changes in metabolic factors, BP, and body composition.

Results: The 25-hydroxyvitamin D (25-OH-D)-level was <50 nmol/l in 76% of the patients before PTX. After PTX, glucose, insulin, and IGF1 decreased, while the 25-OH-D and the IGF-binding protein 1 increased and remained unchanged at follow-up after study medication. One year of vitamin D supplementation resulted in lower parathyroid hormone (PTH) (40 (34-52) vs 49 (38-66) ng/l) and higher 25-OH-D (76 (65-93) vs 49 (40-62) nmol/l; P<0.05). Other laboratory parameters were stable compared with after PTX. Systolic BP decreased and total bone mineral content increased in both groups.

Conclusion: Except for the lowering of the PTH level, no additive effect of vitamin D supplementation was seen. However, PTX proved effective in reducing insulin resistance.

Figures

Figure 1
Figure 1
Flow chart of the study.

References

    1. Hedback GM, Oden AS. Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. Journal of Internal Medicine. 2002;251:476–483. doi: 10.1046/j.1365-2796.2002.00984.x.
    1. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A. Clinical presentation of primary hyperparathyroidism in Europe – nationwide cohort analysis on mortality from nonmalignant causes. Journal of Bone and Mineral Research. 2002;17(Suppl 2):N68–N74.
    1. Farahnak P, Larfars G, Sten-Linder M, Nilsson IL. Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. Journal of Clinical Endocrinology and Metabolism. 2011;96:2112–2118. doi: 10.1210/jc.2011-0238.
    1. Walker MD, Fleischer JB, Di Tullio MR, Homma S, Rundek T, Stein EM, Zhang C, Taggart T, McMahon DJ, Silverberg SJ. Cardiac structure and diastolic function in mild primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism. 2010;95:2172–2179. doi: 10.1210/jc.2009-2072.
    1. Lundgren E, Ljunghall S, Akerstrom G, Hetta J, Mallmin H, Rastad J. Case–control study on symptoms and signs of "asymptomatic" primary hyperparathyroidism. Surgery. 1998;124:980–985. doi: 10.1016/S0039-6060(98)70038-8. discussion 985–986.
    1. Hagstrom E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundstrom J, Melhus H, Held C, Lind L, Michaelsson K, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119:2765–2771. doi: 10.1161/CIRCULATIONAHA.108.808733.
    1. Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, Sikaris K, Ebeling PR, Daly RM. Low serum 25-hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab) Journal of Clinical Endocrinology and Metabolism. 2012;97:1953–1961. doi: 10.1210/jc.2011-3187.
    1. Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, Sikaris K, Grantham N, Ebeling PR, Daly RM. Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study) Diabetes Care. 2011;34:1133–1138. doi: 10.2337/dc10-2167.
    1. Burgaz A, Orsini N, Larsson SC, Wolk A. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. Journal of Hypertension. 2011;29:636–645. doi: 10.1097/HJH.0b013e32834320f9.
    1. Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, Lappe DL, Muhlestein JB. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. American Journal of Cardiology. 2010;106:963–968. doi: 10.1016/j.amjcard.2010.05.027.
    1. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. New England Journal of Medicine. 2001;345:1291–1297. doi: 10.1056/NEJMoa003417.
    1. Lemne C, Brismar K. Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome – a study in borderline hypertension. Blood Pressure. 1998;7:89–95.
    1. Brismar K, Gutniak M, Povoa G, Werner S, Hall K. Insulin regulates the 35 kDa IGF binding protein in patients with diabetes mellitus. Journal of Endocrinological Investigation. 1988;11:599–602.
    1. Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A, Sampayo J, Taylor W, Fraser W, White A, et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia. 2001;44:333–339. doi: 10.1007/s001250051623.
    1. Unden AL, Elofsson S, Brismar K. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study. Clinical Endocrinology. 2005;63:94–102. doi: 10.1111/j.1365-2265.2005.02306.x.
    1. Petersson U, Ostgren CJ, Brudin L, Brismar K, Nilsson PM. Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the Soderakra Cardiovascular Risk Factor Study. Diabetes & Metabolism. 2009;35:198–205. doi: 10.1016/j.diabet.2008.11.003.
    1. Hellenius ML, Brismar KE, Berglund BH, de Faire UH. Effects on glucose tolerance, insulin secretion, insulin-like growth factor 1 and its binding protein, IGFBP-1, in a randomized controlled diet and exercise study in healthy, middle-aged men. Journal of Internal Medicine. 1995;238:121–130. doi: 10.1111/j.1365-2796.1995.tb00909.x.
    1. Valcour A, Blocki F, Hawkins DM, Rao SD. Effects of age and serum 25-OH-vitamin D on serum parathyroid hormone levels. Journal of Clinical Endocrinology and Metabolism. 2012;97:3989–3995. doi: 10.1210/jc.2012-2276.
    1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41. doi: 10.1159/000180580.
    1. Bilezikian JP, Khan AA, Potts JT., Jr Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. Journal of Clinical Endocrinology and Metabolism. 2009;94:335–339. doi: 10.1210/jc.2008-1763.
    1. Povoa G, Roovete A, Hall K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinologica. 1984;107:563–570.
    1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi: 10.1007/BF00280883.
    1. Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. Journal of Endocrinological Investigation. 2006;29:511–515.
    1. Nordenstrom E, Westerdahl J, Bergenfelz A. Long-term follow-up of patients with elevated PTH levels following successful exploration for primary hyperparathyroidism. World Journal of Surgery. 2004;28:570–575.
    1. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP, Liu H, Lane MA, Mullan RJ, Hazem A, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism. 2011;96:1931–1942. doi: 10.1210/jc.2011-0398.
    1. Leu M, Giovannucci E. Vitamin D: epidemiology of cardiovascular risks and events. Best Practice & Research. Clinical Endocrinology & Metabolism. 2011;25:633–646. doi: 10.1016/j.beem.2011.04.001.
    1. Anderson JL, Vanwoerkom RC, Horne BD, Bair TL, May HT, Lappe DL, Muhlestein JB. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? American Heart Journal. 2011;162:331–339. doi: 10.1016/j.ahj.2011.05.005.
    1. Rejnmark L, Avenell A, Masud T, Anderson F, Meyer HE, Sanders KM, Salovaara K, Cooper C, Smith HE, Jacobs ET, et al. Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. Journal of Clinical Endocrinology and Metabolism. 2012;97:2670–2681. doi: 10.1210/jc.2011-3328.
    1. Hagstrom E, Hellman P, Lundgren E, Lind L, Arnlov J. Serum calcium is independently associated with insulin sensitivity measured with euglycaemic–hyperinsulinaemic clamp in a community-based cohort. Diabetologia. 2007;50:317–324. doi: 10.1007/s00125-006-0532-9.
    1. Ayturk S, Gursoy A, Bascil Tutuncu N, Ertugrul DT, Guvener Demirag N. Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism. 2006;91:4260–4263. doi: 10.1210/jc.2005-2825.
    1. Bollerslev J, Rosen T, Mollerup CL, Nordenstrom J, Baranowski M, Franco C, Pernow Y, Isaksen GA, Godang K, Ueland T, et al. Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism. 2009;94:2255–2261. doi: 10.1210/jc.2008-2742.
    1. Rubin MR, Silverberg SJ. Glucose intolerance and primary hyperparathyroidism: an unresolved relationship. Endocrine. 2012;42:231–233. doi: 10.1007/s12020-012-9674-3.
    1. Nilsson IL, Rastad J, Johansson K, Lind L. Endothelial vasodilatory function and blood pressure response to local and systemic hypercalcemia. Surgery. 2001;130:986–990. doi: 10.1067/msy.2001.118368.
    1. Farahnak P, Ring M, Caidahl K, Farnebo LO, Eriksson MJ, Nilsson IL. Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy. European Journal of Endocrinology. 2010;163:461–467. doi: 10.1530/EJE-10-0201.
    1. Kannel WB, Vasan RS, Levy D. Is the relation of systolic blood pressure to risk of cardiovascular disease continuous and graded, or are there critical values? Hypertension. 2003;42:453–456. doi: 10.1161/01.HYP.0000093382.69464.C4.
    1. Staessen JA, Asmar R, De Buyzere M, Imai Y, Parati G, Shimada K, Stergiou G, Redon J, Verdecchia P. Task force II: blood pressure measurement and cardiovascular outcome. Blood Pressure Monitoring. 2001;6:355–370. doi: 10.1097/00126097-200112000-00016.
    1. Luigi P, Chiara FM, Laura Z, Cristiano M, Giuseppina C, Luciano C, Giuseppe P, Sabrina C, Susanna S, Antonio C, et al. Arterial hypertension, metabolic syndrome and subclinical cardiovascular organ damage in patients with asymptomatic primary hyperparathyroidism before and after parathyroidectomy: preliminary results. International Journal of Endocrinology. 2012;2012:408295. doi: 10.1155/2012/408295.
    1. Feldstein CA, Akopian M, Pietrobelli D, Olivieri A, Garrido D. Long-term effects of parathyroidectomy on hypertension prevalence and circadian blood pressure profile in primary hyperparathyroidism. Clinical and Experimental Hypertension. 2010;32:154–158. doi: 10.3109/10641960903254471.
    1. Letizia C, Ferrari P, Cotesta D, Caliumi C, Cianci R, Cerci S, Petramala L, Celi M, Minisola S, D'Erasmo E, et al. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. Journal of Human Hypertension. 2005;19:901–906. doi: 10.1038/sj.jhh.1001907.
    1. Rydberg E, Birgander M, Bondeson AG, Bondeson L, Willenheimer R. Effect of successful parathyroidectomy on 24-hour ambulatory blood pressure in patients with primary hyperparathyroidism. International Journal of Cardiology. 2010;142:15–21. doi: 10.1016/j.ijcard.2008.12.027.
    1. Nilsson IL, Aberg J, Rastad J, Lind L. Circadian cardiac autonomic nerve dysfunction in primary hyperparathyroidism improves after parathyroidectomy. Surgery. 2003;134:1013–1019. doi: 10.1016/j.surg.2003.07.017. discussion 1019.
    1. Nilsson IL, Aberg J, Rastad J, Lind L. Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery. 1999;126:1049–1055. doi: 10.1067/msy.2099.101422.
    1. Kosch M, Hausberg M, Vormbrock K, Kisters K, Gabriels G, Rahn KH, Barenbrock M. Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovascular Research. 2000;47:813–818. doi: 10.1016/S0008-6363(00)00130-9.
    1. Fallo F, Camporese G, Capitelli E, Andreozzi GM, Mantero F, Lumachi F. Ultrasound evaluation of carotid artery in primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism. 2003;88:2096–2099. doi: 10.1210/jc.2002-021837.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다